Wall Street brokerages expect Entellus Medical, Inc. (NASDAQ:ENTL) to announce sales of $21.03 million for the current quarter, Zacks reports. Two analysts have issued estimates for Entellus Medical’s earnings, with the lowest sales estimate coming in at $21.00 million and the highest estimate coming in at $21.05 million. Entellus Medical posted sales of $17.88 million during the same quarter last year, which suggests a positive year over year growth rate of 17.6%. The business is expected to report its next earnings report on Thursday, November 2nd.

On average, analysts expect that Entellus Medical will report full-year sales of $21.03 million for the current financial year. For the next year, analysts expect that the company will post sales of $102.19 million per share, with estimates ranging from $101.08 million to $103.29 million. Zacks’ sales calculations are a mean average based on a survey of sell-side analysts that follow Entellus Medical.

Entellus Medical (NASDAQ:ENTL) last released its quarterly earnings results on Thursday, August 3rd. The medical technology company reported ($0.37) EPS for the quarter, missing analysts’ consensus estimates of ($0.34) by $0.03. The company had revenue of $22.10 million during the quarter, compared to analysts’ expectations of $21.87 million. Entellus Medical had a negative net margin of 41.11% and a negative return on equity of 66.04%. The company’s quarterly revenue was up 18.0% compared to the same quarter last year. During the same period in the previous year, the company posted ($0.27) earnings per share.

ENTL has been the subject of a number of recent research reports. Canaccord Genuity reiterated a “buy” rating and set a $22.00 price objective on shares of Entellus Medical in a research note on Wednesday, April 12th. Zacks Investment Research upgraded Entellus Medical from a “sell” rating to a “hold” rating in a research note on Tuesday, April 25th. William Blair reiterated an “outperform” rating on shares of Entellus Medical in a research note on Wednesday, May 10th. ValuEngine cut Entellus Medical from a “sell” rating to a “strong sell” rating in a research note on Tuesday, May 23rd. Finally, BidaskClub cut Entellus Medical from a “strong-buy” rating to a “buy” rating in a research note on Saturday, July 8th. Two research analysts have rated the stock with a sell rating, four have issued a hold rating and four have issued a buy rating to the company. The stock currently has an average rating of “Hold” and an average target price of $21.83.

Shares of Entellus Medical (ENTL) opened at 16.75 on Tuesday. The company has a 50-day moving average price of $16.33 and a 200-day moving average price of $15.03. Entellus Medical has a 52-week low of $11.47 and a 52-week high of $22.63. The stock’s market capitalization is $367.09 million.

Several hedge funds and other institutional investors have recently bought and sold shares of the company. Royce & Associates LP boosted its position in Entellus Medical by 288.4% in the first quarter. Royce & Associates LP now owns 167,000 shares of the medical technology company’s stock valued at $2,305,000 after buying an additional 124,000 shares in the last quarter. Cortina Asset Management LLC boosted its position in Entellus Medical by 22.6% in the first quarter. Cortina Asset Management LLC now owns 412,323 shares of the medical technology company’s stock valued at $5,690,000 after buying an additional 75,879 shares in the last quarter. William Blair Investment Management LLC boosted its position in Entellus Medical by 1,017.0% in the first quarter. William Blair Investment Management LLC now owns 390,334 shares of the medical technology company’s stock valued at $5,387,000 after buying an additional 355,388 shares in the last quarter. Blair William & Co. IL acquired a new position in Entellus Medical during the first quarter valued at $1,229,000. Finally, Frontier Capital Management Co. LLC acquired a new position in Entellus Medical during the first quarter valued at $6,464,000. Hedge funds and other institutional investors own 76.84% of the company’s stock.

TRADEMARK VIOLATION WARNING: This story was originally reported by American Banking News and is the property of of American Banking News. If you are viewing this story on another domain, it was illegally copied and republished in violation of United States and international copyright & trademark law. The legal version of this story can be accessed at https://www.americanbankingnews.com/2017/08/08/zacks-brokerages-anticipate-entellus-medical-inc-nasdaqentl-will-post-quarterly-sales-of-21-03-million.html.

Entellus Medical Company Profile

Entellus Medical, Inc is a medical technology company. The Company is focused on delivering patient and physician experiences through products designed for the minimally invasive treatment of chronic and recurrent sinusitis in both adult and pediatric patients. Its three core product lines, XprESS Multi-Sinus Dilation Systems, MiniFESS Surgical Instruments, and FocESS Imaging & Navigation, are designed to enable ear, nose and throat (ENT), physicians to perform a range of procedures in the ENT physician office and to simplify operating room-based treatment.

Get a free copy of the Zacks research report on Entellus Medical (ENTL)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Entellus Medical (NASDAQ:ENTL)

Receive News & Ratings for Entellus Medical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Entellus Medical Inc. and related companies with MarketBeat.com's FREE daily email newsletter.